PATIENTS WHO HAVE MBC WITH VISCERAL AND MULTIPLE METASTASES OFTEN HAVE LESS FAVORABLE OUTCOMES

There is lower median survival time for patients who develop visceral metastases vs nonvisceral metastases5,a
Nonvisceral (23.2 months) vs visceral (10.9 months) metastatic breast cancer (MBC) median survival comparison from a retrospective analysis - chart Nonvisceral (23.2 months) vs visceral (10.9 months) metastatic breast cancer (MBC) median survival comparison from a retrospective analysis - chart
  • A retrospective database analysis of 111 women at a single center in Canada between 2005 and 2007 found that about 67%-73% of patients with metastatic breast cancer (MBC) developed visceral metastases.19 A retrospective analysis of 6 clinical studies between 1983 and 2001 (N=640) found that in 57%-74% of patients, visceral metastases developed as the dominant metastatic site9
  • Further studies demonstrate that up to 85% of patients will develop visceral metastases at some point in the course of their disease7,20-22
  • Visceral metastases are associated with more aggressive MBC compared with nonvisceral metastases; patients tend to have worse outcomes5
The number of metastatic sites is associated with more aggressive MBCa
  • The presence of multiple metastatic lesions or sites is associated with poor prognosis in patients with MBC6
  • Patients with MBC who present metastases at ≥3 sites are likely to have a comparatively less favorable outcome than those with ≤2 metastatic sites8
  • a Univariate survival analysis from a retrospective database of 346 patients diagnosed with MBC after first recurrence between 1970 and 1991. All patients had undergone surgery for primary breast cancer and may have received radiation, hormonal therapy, and/or chemotherapy for metastatic disease.5
    All patients had undergone surgery for primary breast cancer and may have received radiation, hormonal therapy, and/or chemotherapy for metastatic disease.5
  • More Detail on Multiple Metastases

    THERE IS LOWER MEDIAN SURVIVAL TIME FOR PATIENTS WITH INCREASING NUMBER OF METASTATIC SITES6,a

    MBC median survival comparison: 3 or more metastatic sites: median survival of 19.3 months, 2 metastatic sites: median survival of 24.5 months, 1 metastatic site: median survival of 31.3 months - chartMBC median survival comparison: 3 or more metastatic sites: median survival of 19.3 months, 2 metastatic sites: median survival of 24.5 months, 1 metastatic site: median survival of 31.3 months - chart
    • aUnivariate survival analysis of 1430 patients from 8 consecutive prospective trials conducted between 1977 and 1992 of anthracycline-based first-line chemotherapy in MBC.
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL